PASG Q3 2025 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena

PASGPassage Bio, Inc.

$29M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$8M

EPS (Diluted)

$-2.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$74M

Total Liabilities

$43M

Stockholders' Equity

$31M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$9M	-$21M	+58.2%
Net Income	-$8M	-$19M	+59.9%